Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Revenue (2022 - 2025)

Historic Revenue for Abivax (ABVX) over the last 3 years, with Q3 2025 value amounting to $91.7 million.

  • Abivax's Revenue rose 75255.63% to $91.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.7 million, marking a year-over-year increase of 45124.71%. This contributed to the annual value of $13.3 million for FY2024, which is 16613.25% up from last year.
  • Per Abivax's latest filing, its Revenue stood at $91.7 million for Q3 2025, which was up 75255.63% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Abivax's Revenue ranged from a high of $91.7 million in Q3 2025 and a low of -$32.2 million during Q4 2024
  • For the 3-year period, Abivax's Revenue averaged around $12.8 million, with its median value being $6.5 million (2025).
  • As far as peak fluctuations go, Abivax's Revenue tumbled by 9963782.27% in 2024, and later soared by 75255.63% in 2025.
  • Quarter analysis of 3 years shows Abivax's Revenue stood at -$32278.2 in 2023, then crashed by 99637.82% to -$32.2 million in 2024, then skyrocketed by 384.96% to $91.7 million in 2025.
  • Its last three reported values are $91.7 million in Q3 2025, $5.9 million for Q2 2025, and $7.0 million during Q1 2025.